Article Text

Download PDFPDF
Adalimumab-induced bronchospasm: not a class effect
  1. R Janssen1,
  2. I Krivokuca2,
  3. A A Kruize3,
  4. L Koenderman2,
  5. J-W J Lammers2
  1. 1
    Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands
  2. 2
    Department of Pulmonology, University Medical Centre Utrecht, Utrecht, The Netherlands
  3. 3
    Department of Rheumatology, University Medical Centre Utrecht, Utrecht, The Netherlands
  1. Dr R Janssen, Department of Pulmonology, St Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands; r.janssen{at}antonius.net

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

A 48-year-old man with rheumatoid arthritis (RA) was admitted with shortness of breath due to bronchospasm and hypoxaemia (Pao2 5.9 kPa (44 mm Hg)). He had no history of pulmonary disease or allergy/atopy. About 3 years before this admission he was treated with infliximab. He was switched from infliximab to etanercept because of its more convenient subcutaneous form of administration. He was switched from etanercept to adalimumab because his RA persistently flared on the former treatment. Three days before admission he had received adalimumab for the second time. Blood count showed a new eosinophilia of 0.8×109/l (normal range 0–0.4). He …

View Full Text

Footnotes

  • Funding: None.

  • Competing interests: None